Bristol Myers Squibb (BMY) Equity Ratio (2009 - 2026)
Bristol Myers Squibb (BMY) reported Equity Ratio of 0.23 for Q1 2026, up 7245.55% year-over-year from 0.0 in Q1 2025, and up 13.11% quarter-over-quarter from 0.21 in Q4 2025.
Bristol Myers Squibb (BMY) Equity Ratio (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (BMY) has 18 years of Equity Ratio data on file, last reported at 0.23 in Q1 2026.
- Equity Ratio for Q1 2026 came in at 0.23, up 7245.55% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.23 (up 7245.55% YoY), and the FY2025 annual result was 0.21, up 27.41% from the prior year.
- Equity Ratio grew to 0.23 in Q1 2026 per BMY's latest filing, from 0.21 in the prior quarter.
- Over five years, Equity Ratio peaked at 0.31 in Q3 2023 and troughed at 0.44 in Q1 2024.
- A 5-year average of 0.01 and a median of 0.0 in 2024 frame the typical range for Equity Ratio.
- The sharpest annual moves came in 2024 and 2026: Equity Ratio sank 14346.95% in 2024, then soared 7245.55% in 2026.
- A 5-year view of Equity Ratio shows it stood at 0.01 in 2022, then decreased by 22.79% to 0.02 in 2023, then jumped by 1091.18% to 0.16 in 2024, then grew by 27.41% to 0.21 in 2025, then advanced by 13.11% to 0.23 in 2026.
- Business Quant data shows BMY's Equity Ratio at 0.23 in Q1 2026, 0.21 in Q4 2025, and 0.19 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 0.27 |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 0.40 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -0.05 |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 0.36 |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 0.10 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 0.42 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 0.43 |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 0.23 |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.23 |
| Dec 31, 2025 | 0.21 |
| Sep 30, 2025 | 0.19 |
| Jun 30, 2025 | 0.00 |
| Mar 31, 2025 | 0.00 |
| Dec 31, 2024 | 0.16 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | -0.44 |
| Dec 31, 2023 | -0.02 |
| Sep 30, 2023 | 0.31 |
| Jun 30, 2023 | -0.42 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | -0.01 |
| Sep 30, 2022 | -0.01 |
| Jun 30, 2022 | -0.35 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 0.22 |
| Sep 30, 2021 | 0.40 |
| Jun 30, 2021 | 0.00 |